Mutations in the PIK3CA gene are present in about 4% to 36% of cancers such as breast, ovarian, endometrial and colorectal cancer, among others.

国际大型EQA项目揭秘PIK3CA基因检测在乳腺癌治疗中的关键角色。 浸润性乳腺癌（IBC）是一种侵袭性生长的乳腺实质恶性肿瘤 [1] 。其中激素受体阳性 ...

国际大型EQA项目揭秘PIK3CA基因检测在乳腺癌治疗中的关键角色。 浸润性乳腺癌（IBC）是一种侵袭性生长的乳腺实质恶性肿瘤[1]。其中激素受体阳性 ...

一项韩国回顾性分析揭示PIK3CA基因突变在原发灶与转移灶间总体一致率达87.8%。 乳腺癌作为全球女性中最常见的恶性肿瘤 [1] ，其早期诊断与治疗对 ...

2. Grade 3-4 adverse events were reported in 88.3% of the inavolisib group vs 82.1% in the placebo group Evidence Rating Level: 1 (Excellent) Study Rundown: PIK3CA mutations are present in 35-40% of ...

这项研究评估了与单独使用氟维司群（Fulvestrant）和哌柏西利（palbociclib）相比，使用PI3Kα抑制剂Inavolisib（代号：GDC-0077）联合哌柏西利和氟维司群在携带PIK3CA突变、HR阳性、HER2阴性乳腺癌患者中的疗效和安全性。 此前，2024年3月，国家药监局药品审评中心（CDE ...

Mutations in the PIK3CA gene are present in about 4% to 36% of cancers such as breast, ovarian, endometrial and colorectal cancer, among others.

Inavolisib (Itovebi) plus fulvestrant and palbociclib (Ibrance) led to a statistically significant and clinically meaningful benefit in progression-free survival (PFS) vs fulvestrant and palbociclib ...

The genetic basis of most traits is highly polygenic and dominated by non-coding alleles. It is widely assumed that such alleles exert small regulatory effects on the expression of cis-linked genes.

Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in ...